Last $5.90 USD
Change Today -0.50 / -7.81%
Volume 2.5K
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

myos corp (MYOS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/14 - $16.85
52 Week Low
01/30/15 - $5.87
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYOS CORP (MYOS)

Related News

No related news articles were found.

myos corp (MYOS) Related Businessweek News

No Related Businessweek News Found

myos corp (MYOS) Details

MYOS Corporation, a development-stage biotherapeutics and nutritional products company, focuses on the discovery, development, and commercialization of nutritional supplements, functional foods, therapeutic products, and other technologies for maintaining or improving the health and performance of muscle tissue. It develops MYO-T12, a dietary supplement product for optimizing biological activity. The company was formerly known as Atlas Therapeutics Corporation and changed its name to MYOS Corporation in May 2012. MYOS Corporation was founded in 2007 and is based in Cedar Knolls, New Jersey.

4 Employees
Last Reported Date: 05/15/14
Founded in 2007

myos corp (MYOS) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $299.0K
Vice President and Corporate Controller
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

myos corp (MYOS) Key Developments

MYOS Corporation's Preclinical Study of Fortetropin's Mechanism of Action Demonstrate Regulatory Effects on Three Key Muscle Health Pathways

MYOS Corporation announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin™ exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. Myostatin is a naturally occurring regulatory protein which prevents muscle growth. Myostatin serum levels increase as people age which can lead to age-related muscle loss or sarcopenia. Fortetropin's ability to reduce serum myostatin levels has been clinically proven. Regulation of myostatin may be a key element in the treatment of sarcopenia. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the Company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.

MYOS Corporation Appoints EisnerAmper LLP as Independent Registered Public Accounting Firm

MYOS Corporation Company held its annual meeting of stockholders on December 22, 2014 ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014.

MYOS Corporation Approves Amendment to Articles of Incorporation

MYOS Corporation held its annual meeting of stockholders on December 22, 2014, approved a Certificate of amendment to its articles of incorporation, as amended (the 'Articles of Incorporation') with the Secretary of State of the State of Nevada to effect an increase in the aggregate number of authorized shares of common stock by 2,000,000 shares to 8,000,000 shares.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYOS:US $5.90 USD -0.50

MYOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MYOS.
View Industry Companies

Industry Analysis


Industry Average

Valuation MYOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.9x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYOS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at